Amphastar Pharmaceuticals, Inc. (AMPH) Balance Sheet

The increase in total assets is primarily driven by a rise in PPE net from $320.4M to $389.1M, reflecting continued investment in manufacturing capabilities. Retained earnings grew steadily from $452.4M to $703.6M, suggesting consistent profitability retention. However, the balance sheet expansion is not matched by revenue growth, which has been flat to negative, implying that asset growth may be outpacing operational performance.

The debt level has grown by approximately $61M over the period, likely related to the Baqsimi acquisition. Despite the increase, the D/E ratio has remained relatively stable, suggesting that equity growth has kept pace. The company's leverage is moderate compared to peers like Perrigo (D/E 1.35), but the absolute debt level is substantial. Given the company's stable cash flow generation, the debt appears manageable, but investors should monitor refinancing risk if interest rates rise.

The rise in PPE suggests ongoing investment in manufacturing capacity, consistent with the company's vertical integration strategy. Goodwill is negligible, which is unusual for a company that made a significant acquisition like Baqsimi, implying that the purchase price was allocated primarily to identifiable intangibles rather than goodwill. This may indicate a lower risk of future impairment charges, but the amortization of intangibles could pressure earnings.

The growth in equity is almost entirely attributable to retained earnings, which increased by $251.2M over the period. This indicates that the company is not heavily reliant on external equity financing. However, the company has also been active in share repurchases, with $45.2M in buybacks in 2026Q2, which may offset some of the retained earnings growth. The quality of equity is high, as it is backed by tangible asset growth and consistent profitability.

The current ratio has remained above 2.0 throughout the period, indicating a strong ability to cover short-term obligations. Cash levels have fluctuated but remain substantial, providing a buffer against operational shocks. However, the current ratio dipped to 2.40 in 2026Q2 from a peak of 4.02 in 2025Q4, suggesting a slight tightening in liquidity, possibly due to increased debt or working capital needs. The company's cash position is adequate to fund ongoing operations and debt service.